An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

Regarding distributions, we view Novartis’ dividends and share repurchases as about right. Novartis has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

While Welireg (belzutifan) has outperformed Afinitor (everolimus) in OS at 12 months and 24 months, the results have not achieved statistical significance. The OS gap between Welireg and Afinitor ...

Patients with previously treated advanced clear cell renal cell carcinoma (RCC) — a type of kidney cancer — experienced improvements in progression and response via treatment with Welireg (belzutifan) ...

Treatment with belzutifan (Welireg) demonstrated significant benefits over everolimus (Afinitor) in treating advanced clear cell renal cell carcinoma (RCC). Specifically, patients who received ...

Afinitor (everolimus) is a prescription drug that’s used to treat some types of cancer, seizures, and certain tumors. This drug can interact with other medications and some supplements.

NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019. The new decision means that Afinitor will be ...

Afinitor (everolimus) has been approved in the EU for advanced, progressive, non-functional neuroendocrine tumours (NETs) of gastrointestinal and lung origin and is the first oral therapy for this ...